Repository logo
 
Publication

Biomarker of Chronic Alcohol Abuse – Carbohydrate-deficient Transferrin (CDT): Methodology Verification

dc.contributor.authorGomes, Filomena
dc.contributor.authorCosta, Alcina
dc.contributor.authorFernandes, Lília
dc.contributor.authorSilva, Ana Maria V. da
dc.contributor.authorVasconcelos, Miguel
dc.contributor.authorMiranda, Armandina
dc.date.accessioned2024-01-05T14:57:13Z
dc.date.available2024-01-05T14:57:13Z
dc.date.issued2023-04-14
dc.description.abstractIntroduction: Transferrin is a glycoprotein synthesized in hepatocytes that can appear with different isomorphic forms in the plasma, acquiring different levels of sialization (1,2). In a healthy person, penta, tetra and trisial isoforms are detectible in plasma. However, in an alcohol abuse and/or dependence, asialo, monosialo and disialotransferrin isoforms are also present called carbohydrate-deficient transferrin (CDT) (3) . This is considered a specific biomarker of alcohol abusive and/or dependence, being useful in the diagnosis and monitoring of this pathology (4) . Aim: Verify compliance with the requirements of the manufacturer of the capillary electrophoresis method in laboratory practice and its suitability in determining the CDT. Materials and methods: The MiniCap System (Sebia) was used with calibrators traceable to the IFCC international reference procedure and normal and pathological internal control samples. Repeatability and intermediate precision tests were performed on control samples. From participation in External Quality Assessment (EQA) program (5 rounds - 2 samples each), Bias%, Deviation Index (DI) and Total Laboratory Error (TELab) were obtained. The Measurement Uncertainty was calculated by the Top Down Method (combined and expanded with a factor of 1.96), using the internal (CV%) and external (Bias%) quality control results. Results: In the repeatability tests, normal control samples (n=22, mean = 1.4%) were obtained, CV = 5.7%; for the pathological sample (n=24, mean = 5.4%), CV = 2.2%. In intermediate precision tests for the normal control sample, (n= 12, mean = 1.4%), CV = 6.7%; for the pathological sample (n=12, mean = 5.3%), CV = 4.9%. In samples from EQA program, mean Bias = -1.0% and TELab = 11.5. In the evaluation of the method by DI, 1 satisfactory, 7 good and 2 excellent results were obtained. The obtained Expanded Uncertainty (1.3% ± 0.3) is consistent with that indicated by the manufacturer. Conclusion: The TELab obtained meets Westgard`s desirable specifications (5) , being considered an appropriate methodology for use in laboratory practise for diagnosis. However, it is considered important to monitor the method with Internal Control samples, and participate in EQA programs, as well as periodic evaluation of Quality Indicators.pt_PT
dc.description.versionN/Apt_PT
dc.identifier.urihttp://hdl.handle.net/10400.18/8866
dc.language.isoengpt_PT
dc.peerreviewednopt_PT
dc.publisherInstituto Nacional de Saúde Doutor Ricardo Jorge, IPpt_PT
dc.subjectChronic Alcohol Abusept_PT
dc.subjectCDT - Carbohydrate-deficient Transferrinpt_PT
dc.subjectAlcohol Biomarkerpt_PT
dc.subjectCapillary Electrophoresispt_PT
dc.subjectLaboratory Quality Assessmentpt_PT
dc.subjectPerturbações do Desenvolvimento Infantil e Saúde Mentalpt_PT
dc.titleBiomarker of Chronic Alcohol Abuse – Carbohydrate-deficient Transferrin (CDT): Methodology Verificationpt_PT
dc.typeconference object
dspace.entity.typePublication
oaire.citation.conferencePlacePorto, Portugalpt_PT
oaire.citation.title15ª Reunião Científica da Sociedade Portuguesa de Medicina Laboratorial, 14,15 abril 2023pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typeconferenceObjectpt_PT

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
CDT_Poster_SPML_6-04-2023_FG_LF AGC.pdf
Size:
846.88 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: